Business
CNS Pharmaceuticals Announces Collaboration with European Partner to Expand Clinical Trials to Pediatric Brain Tumors
In addition to potential upcoming Phase II clinical trial evaluating the efficacy of Berubicin in patients with Glioblastoma HOUSTON, Feb. 11, 2020
About this update from Cns Pharmaceuticals, Inc.
[{"type":"text","content":"In addition to potential upcoming Phase II clinical trial evaluating the efficacy of Berubicin in patients with Glioblastoma\n\n\nHOUSTON, Feb. 11, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (\"CNS\" or the \"Company\"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced its plan to initiate a Phase I clinical trial for Berubicin in pediatric brain cancer in Poland in collaboration with WPD Pharmaceuticals, Inc. (CSE: WBIO) (\"WPD\"), a Polish corporation founded by Dr. Waldemar Priebe, the founder of the Company.\nThe Company, in collaboration with WPD, will conduct the upcoming Phase I clinical trial at Children's Memorial Health Institute (\"Children's Memorial\"), the largest pediatric hospital in Poland. The Company believes this Phase I trial of Berubicin at Children's Memorial represents the first ever investigation of an anthracycline and topoisomerase II inhibitor in pediatric brain tumors. WPD and CNS are currently working with Children's Memorial to complete documentation for the upcoming study and EMA scientific advice meeting. \nAs previously announced, CNS entered into a sublicense agreement with WPD which granted WPD commercial rights in a limited territory to Berubicin, including research and development. Subsequently, WPD was awarded a $6 million grant from the EU/Polish National Center for Research and Development. WPD plans to utilize funds from the grant to fund the upcoming Phase I trial and CNS is committed to fully support these studies with its internal expertise.\n\"We are extremely excited to further expand the scope of Berubicin and potentially bring a new hope for pediatric brain tumor patients in Poland and subsequently around the world,\" stated John Climaco, CEO of CNS Pharmaceuticals. \"We look forward to initiating what we believe to be the first investigation of a unique topoisomerase II inhibitor that appears to be able to cross the blood-brain barrier in pediatric brain tumors as we continue to drive the clinical development of Berubicin in the upcoming Phase II trial in adult patients.\"\nAbout BerubicinBerubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclin...